/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Introduction Bausch Health Companies Inc. ( we , us , our , the Company or Bausch Health ) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology ( GI ), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counte…
$6.47
+$0.10 (+1.57%)
EOD Sep 1, 2026
17.66% operating margin is respectable but not wide. ROIC at 7.30%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 6.7%, steady but not accelerating. Free cash flow declined 20% despite revenue growth, conversion is weakening.
Free cash flow declined 20% versus the prior year, cash generation momentum has weakened. Net debt of $19.74B represents 19.7x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$10.85B
▲ +6.7% YoY
Net Income (TTM)
-$1.10B
▲ +441.3% YoY
Op. Margin
8.14%
▲ +1.6pp YoY
ROIC
2.50%
▲ +1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.43B
▼ -20.4% YoY
Op. Cash Flow (TTM)
$1.80B
▼ -12.3% YoY
Net Debt
$18.92B
Cash & Equiv.
$1.82B
5Y CAGR: +5.0%
5Y CAGR: +4.4%
Continue Research
SourceComputed from the 10-Q filed 30 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Bausch Health Companies (BHC) trades below a two-stage DCF intrinsic value of about $25.38 per share, so at $6.47 the stock looks undervalued (292.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bausch Health Companies scores 57/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $25.38 per share for BHC, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $19.03. At today's $6.47, that puts the stock about 292.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Bausch Health Companies scores 57 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 8.1% operating margin and a 2.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BHC currently trades below its estimated intrinsic value and scores 57/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.